However, the distribution of tau and β-amyloid offers limited predictive value for determining cognitive decline in AD and are not useful for other neurodegenerative conditions (Leuzy et al., 2019; Bullich et al., 2021; Groot et al., 2022; Pemberton et al., 2022). Here, MAPT is linked to Alzheimer disease.